Protalix BioTherapeutics
PLX
44 hedge funds and large institutions have $160M invested in Protalix BioTherapeutics in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 6 closing their positions.
14% more capital invested
Capital invested by funds: $141M → $160M (+$19.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.13% less ownership
Funds ownership: 3.87% → 3.74% (-0.13%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
2% less funds holding
Funds holding: 45 → 44 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
96% less call options, than puts
Call options by funds: $152K | Put options by funds: $4.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
+$639K |
| 2 |
DAM
Deltec Asset Management
New York
|
+$511K |
| 3 |
BCMU
BlueCrest Capital Management (UK)
St. Peter Port,
Guernsey
|
+$341K |
| 4 |
Morgan Stanley
New York
|
+$242K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$2.72M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$1.14M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$957K |
| 4 |
FRM
Fore Research & Management
New York
|
-$628K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$410K |
PLX Hedge Fund Activity: Q1 2014 in Review
44 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2014, worth a combined $160M — up 14% from $141M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PLX and 5 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.
The largest buyer was Mivtachim The Workers Social Insurance Fund, adding an estimated $639K. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $2.72M sold.
- 44 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2014, down from 45 in Q4 2013.
- Funds reported $160M of Protalix BioTherapeutics stock for Q1 2014, up 14% quarter-over-quarter.
- 5 funds opened new Protalix BioTherapeutics positions in Q1 2014 and 6 closed out, a net change of -1 holder.
- The largest Protalix BioTherapeutics buyer in Q1 2014 was Mivtachim The Workers Social Insurance Fund, an estimated $639K added.
- The largest Protalix BioTherapeutics seller in Q1 2014 was First Eagle Investment Management, an estimated $2.72M sold.
Based on aggregated 13F filings for Q1 2014.